Methods: Seventy-one HDM sensitized allergic patients were enrolled and classified into 4 groups including one control (n=27), SCIT using Hollister-Stier® (n=18, maintenance dose = 750.8±255.3 Allergy Unit), Tyrosine S® (n=16, maintenance dose 14,999.4±2854.4 TU), and Novo-helisen® (n=10, maintenance dose = 3057.1±1268.7 TU). Maintenance dose of Hollister-Stier was determined by the physician, and the other 2 reagents by the provided companies. Specific IgE and sIgG4 to Dermatophagoides farina were measured before and at 13.7 ± 6.54 months after the beginning of SCIT using ImmunoCAP® system.
Results: Mean level of specific IgG4 to Dermatophagoides farina (Gd2) before SCIT was 0.39 ± 0.49 mg/L and found is no difference among the groups (P = 0.118). After SCIT, Gd2 level was significantly increased, but the increases were quite different according to the SCIT groups (p <0.001). Gd2 level was highest in Hollister-Stier® (2.89 ± 1.88 mg/L) compared with Tyrosine S® (0.67 ± 0.52 mg/L) and Novo-helisen®(2.16 ± 2.31 mg/L). Specific IgE to Dermatophagoides farina after SCIT was increased in Hollister-Stier® (12.53 ± 29.78 kUA/L) and Tyrosine S® (2.18 ± 16.34 kUA/L), but decreased in Novo-helisen® (-2.19± 27.20 kUA/L) which were not significantly different. (p=0.429)
Conclusions: Currently available SCIT reagents induce different levels of specific IgG4 and maybe have different efficacy.